OBJECTIVE: The aim of this study was to identify provider characteristics associated with hormone therapy prescribing. METHODS: The study design is cross-sectional. In December 2005, we mailed surveys to providers practicing in two integrated healthcare delivery systems located in the northwestern and northeastern United States; 379 responded (74%) and 249 (49% of total) granted access to their automated data. Data included provider demographics, practice characteristics, and perceptions about hormone therapy. Provider-specific annual hormone therapy prescribing frequency was calculated as days supply of hormone therapy filled divided by the number of visits (among women aged 45-80 y). Factors associated with higher rates of hormone therapy prescribing were identified using bivariate and multivariate analyses. RESULTS: We report results separately for primary care providers (internists and family practitioners) and obstetrician/gynecologists because significant correlates differed in these two groups. For both primary care providers and obstetrician/gynecologists, in multivariate analyses, hormone therapy prescribing varied by site (P < or = 0.002) and years at the healthcare organization (P < or = 0.01). For primary care providers only, higher hormone therapy prescribing was associated with reported expert knowledge of the hormone therapy trials (P < or = 0.001). For obstetrician/gynecologists, higher hormone therapy prescription was related to feeling well prepared to counsel women on hormone therapy (P < or = 0.007), believing that the risks of estrogen with progestogen had been exaggerated (P = 0.04), and seeing younger aged patients (P = 0.03). CONCLUSIONS: After the release of the Women's Health Initiative findings and practicing under similar clinical guidelines, hormone therapy prescribing is associated with providers' confidence, practice location, and time with a healthcare organization.
OBJECTIVE: The aim of this study was to identify provider characteristics associated with hormone therapy prescribing. METHODS: The study design is cross-sectional. In December 2005, we mailed surveys to providers practicing in two integrated healthcare delivery systems located in the northwestern and northeastern United States; 379 responded (74%) and 249 (49% of total) granted access to their automated data. Data included provider demographics, practice characteristics, and perceptions about hormone therapy. Provider-specific annual hormone therapy prescribing frequency was calculated as days supply of hormone therapy filled divided by the number of visits (among women aged 45-80 y). Factors associated with higher rates of hormone therapy prescribing were identified using bivariate and multivariate analyses. RESULTS: We report results separately for primary care providers (internists and family practitioners) and obstetrician/gynecologists because significant correlates differed in these two groups. For both primary care providers and obstetrician/gynecologists, in multivariate analyses, hormone therapy prescribing varied by site (P < or = 0.002) and years at the healthcare organization (P < or = 0.01). For primary care providers only, higher hormone therapy prescribing was associated with reported expert knowledge of the hormone therapy trials (P < or = 0.001). For obstetrician/gynecologists, higher hormone therapy prescription was related to feeling well prepared to counsel women on hormone therapy (P < or = 0.007), believing that the risks of estrogen with progestogen had been exaggerated (P = 0.04), and seeing younger aged patients (P = 0.03). CONCLUSIONS: After the release of the Women's Health Initiative findings and practicing under similar clinical guidelines, hormone therapy prescribing is associated with providers' confidence, practice location, and time with a healthcare organization.
Authors: R E Williams; L Kalilani; D Britt DiBenedetti; X Zhou; A L Granger; S E Fehnel; K B Levine; J Jordan; R V Clark Journal: Climacteric Date: 2008-02 Impact factor: 3.005
Authors: Paul A Fishman; Michael J Goodman; Mark C Hornbrook; Richard T Meenan; Donald J Bachman; Maureen C O'Keeffe Rosetti Journal: Med Care Date: 2003-01 Impact factor: 2.983
Authors: Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: Susan L Lakey; Susan D Reed; Andrea Z LaCroix; Lou Grothaus; Katherine M Newton Journal: J Womens Health (Larchmt) Date: 2010-11-09 Impact factor: 2.681
Authors: Sybil L Crawford; Carolyn J Crandall; Carol A Derby; Samar R El Khoudary; L Elaine Waetjen; Mary Fischer; Hadine Joffe Journal: Menopause Date: 2018-12-21 Impact factor: 2.953
Authors: Adriane Fugh-Berman; Christina Pike McDonald; Alicia M Bell; Emily Catherine Bethards; Anthony R Scialli Journal: PLoS Med Date: 2011-03-15 Impact factor: 11.069